Reports Overview
Key Market Segments
- By Product Type
- Reagents
- Instruments
- Software and Services
- By TECHNIQUE
- Blood Testing
- Tissue Diagnostics
- By CANCER TYPE
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer Types
- By END USER
- Standalone Laboratory
- Hospitals
- Academic and Medical Schools
- Other End User
- By Region
- North America
- Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
Key Market Players
- Siemens Healthineers
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Olympus Corporation
- Qiagen NV
- Hologic, Inc.
- Agilent Technologies
- Roche Diagnostics
- GlaxoSmithKline
- Abbott Laboratories
Table of contents
-
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
-
CHAPTER 2: EXECUTIVE SUMMARY
-
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
-
3.5. Market Dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
-
CHAPTER 4: CANCER IVD MARKET, BY PRODUCT TYPE
-
4.1. Market Overview
-
4.1.1 Market Size and Forecast, By Product Type
-
4.2. Reagents
-
4.2.1. Key Market Trends, Growth Factors and Opportunities
-
4.2.2. Market Size and Forecast, By Region
-
4.2.3. Market Share Analysis, By Country
-
4.3. Instruments
-
4.3.1. Key Market Trends, Growth Factors and Opportunities
-
4.3.2. Market Size and Forecast, By Region
-
4.3.3. Market Share Analysis, By Country
-
4.4. Software And Services
-
4.4.1. Key Market Trends, Growth Factors and Opportunities
-
4.4.2. Market Size and Forecast, By Region
-
4.4.3. Market Share Analysis, By Country
-
CHAPTER 5: CANCER IVD MARKET, BY TECHNIQUE
-
5.1. Market Overview
-
5.1.1 Market Size and Forecast, By Technique
-
5.2. Blood Testing
-
5.2.1. Key Market Trends, Growth Factors and Opportunities
-
5.2.2. Market Size and Forecast, By Region
-
5.2.3. Market Share Analysis, By Country
-
5.3. Tissue Diagnostics
-
5.3.1. Key Market Trends, Growth Factors and Opportunities
-
5.3.2. Market Size and Forecast, By Region
-
5.3.3. Market Share Analysis, By Country
-
CHAPTER 6: CANCER IVD MARKET, BY CANCER TYPE
-
6.1. Market Overview
-
6.1.1 Market Size and Forecast, By Cancer Type
-
6.2. Breast Cancer
-
6.2.1. Key Market Trends, Growth Factors and Opportunities
-
6.2.2. Market Size and Forecast, By Region
-
6.2.3. Market Share Analysis, By Country
-
6.3. Colorectal Cancer
-
6.3.1. Key Market Trends, Growth Factors and Opportunities
-
6.3.2. Market Size and Forecast, By Region
-
6.3.3. Market Share Analysis, By Country
-
6.4. Lung Cancer
-
6.4.1. Key Market Trends, Growth Factors and Opportunities
-
6.4.2. Market Size and Forecast, By Region
-
6.4.3. Market Share Analysis, By Country
-
6.5. Prostate Cancer
-
6.5.1. Key Market Trends, Growth Factors and Opportunities
-
6.5.2. Market Size and Forecast, By Region
-
6.5.3. Market Share Analysis, By Country
-
6.6. Other Cancer Types
-
6.6.1. Key Market Trends, Growth Factors and Opportunities
-
6.6.2. Market Size and Forecast, By Region
-
6.6.3. Market Share Analysis, By Country
-
CHAPTER 7: CANCER IVD MARKET, BY END USER
-
7.1. Market Overview
-
7.1.1 Market Size and Forecast, By End User
-
7.2. Standalone Laboratory
-
7.2.1. Key Market Trends, Growth Factors and Opportunities
-
7.2.2. Market Size and Forecast, By Region
-
7.2.3. Market Share Analysis, By Country
-
7.3. Hospitals
-
7.3.1. Key Market Trends, Growth Factors and Opportunities
-
7.3.2. Market Size and Forecast, By Region
-
7.3.3. Market Share Analysis, By Country
-
7.4. Academic And Medical Schools
-
7.4.1. Key Market Trends, Growth Factors and Opportunities
-
7.4.2. Market Size and Forecast, By Region
-
7.4.3. Market Share Analysis, By Country
-
7.5. Other End User
-
7.5.1. Key Market Trends, Growth Factors and Opportunities
-
7.5.2. Market Size and Forecast, By Region
-
7.5.3. Market Share Analysis, By Country
CHAPTER 8: CANCER IVD MARKET, BY REGION
-
8.1. Market Overview
-
8.1.1 Market Size and Forecast, By Region
-
8.2. North America
-
8.2.1. Key Market Trends and Opportunities
-
8.2.2. Market Size and Forecast, By Product Type
-
8.2.3. Market Size and Forecast, By Technique
-
8.2.4. Market Size and Forecast, By Cancer Type
-
8.2.5. Market Size and Forecast, By End User
-
8.2.6. Market Size and Forecast, By Country
8.2.7. U.S. Cancer Ivd Market
8.2.7.1. Market Size and Forecast, By Product Type
8.2.7.2. Market Size and Forecast, By Technique
8.2.7.3. Market Size and Forecast, By Cancer Type
8.2.7.4. Market Size and Forecast, By End User
8.2.8. Canada Cancer Ivd Market
8.2.8.1. Market Size and Forecast, By Product Type
8.2.8.2. Market Size and Forecast, By Technique
8.2.8.3. Market Size and Forecast, By Cancer Type
8.2.8.4. Market Size and Forecast, By End User
8.2.9. Mexico Cancer Ivd Market
8.2.9.1. Market Size and Forecast, By Product Type
8.2.9.2. Market Size and Forecast, By Technique
8.2.9.3. Market Size and Forecast, By Cancer Type
8.2.9.4. Market Size and Forecast, By End User
-
8.3. Europe
-
8.3.1. Key Market Trends and Opportunities
-
8.3.2. Market Size and Forecast, By Product Type
-
8.3.3. Market Size and Forecast, By Technique
-
8.3.4. Market Size and Forecast, By Cancer Type
-
8.3.5. Market Size and Forecast, By End User
-
8.3.6. Market Size and Forecast, By Country
8.3.7. France Cancer Ivd Market
8.3.7.1. Market Size and Forecast, By Product Type
8.3.7.2. Market Size and Forecast, By Technique
8.3.7.3. Market Size and Forecast, By Cancer Type
8.3.7.4. Market Size and Forecast, By End User
8.3.8. Germany Cancer Ivd Market
8.3.8.1. Market Size and Forecast, By Product Type
8.3.8.2. Market Size and Forecast, By Technique
8.3.8.3. Market Size and Forecast, By Cancer Type
8.3.8.4. Market Size and Forecast, By End User
8.3.9. Italy Cancer Ivd Market
8.3.9.1. Market Size and Forecast, By Product Type
8.3.9.2. Market Size and Forecast, By Technique
8.3.9.3. Market Size and Forecast, By Cancer Type
8.3.9.4. Market Size and Forecast, By End User
8.3.10. Spain Cancer Ivd Market
8.3.10.1. Market Size and Forecast, By Product Type
8.3.10.2. Market Size and Forecast, By Technique
8.3.10.3. Market Size and Forecast, By Cancer Type
8.3.10.4. Market Size and Forecast, By End User
8.3.11. UK Cancer Ivd Market
8.3.11.1. Market Size and Forecast, By Product Type
8.3.11.2. Market Size and Forecast, By Technique
8.3.11.3. Market Size and Forecast, By Cancer Type
8.3.11.4. Market Size and Forecast, By End User
8.3.12. Russia Cancer Ivd Market
8.3.12.1. Market Size and Forecast, By Product Type
8.3.12.2. Market Size and Forecast, By Technique
8.3.12.3. Market Size and Forecast, By Cancer Type
8.3.12.4. Market Size and Forecast, By End User
8.3.13. Rest Of Europe Cancer Ivd Market
8.3.13.1. Market Size and Forecast, By Product Type
8.3.13.2. Market Size and Forecast, By Technique
8.3.13.3. Market Size and Forecast, By Cancer Type
8.3.13.4. Market Size and Forecast, By End User
-
8.4. Asia-Pacific
-
8.4.1. Key Market Trends and Opportunities
-
8.4.2. Market Size and Forecast, By Product Type
-
8.4.3. Market Size and Forecast, By Technique
-
8.4.4. Market Size and Forecast, By Cancer Type
-
8.4.5. Market Size and Forecast, By End User
-
8.4.6. Market Size and Forecast, By Country
8.4.7. China Cancer Ivd Market
8.4.7.1. Market Size and Forecast, By Product Type
8.4.7.2. Market Size and Forecast, By Technique
8.4.7.3. Market Size and Forecast, By Cancer Type
8.4.7.4. Market Size and Forecast, By End User
8.4.8. Japan Cancer Ivd Market
8.4.8.1. Market Size and Forecast, By Product Type
8.4.8.2. Market Size and Forecast, By Technique
8.4.8.3. Market Size and Forecast, By Cancer Type
8.4.8.4. Market Size and Forecast, By End User
8.4.9. India Cancer Ivd Market
8.4.9.1. Market Size and Forecast, By Product Type
8.4.9.2. Market Size and Forecast, By Technique
8.4.9.3. Market Size and Forecast, By Cancer Type
8.4.9.4. Market Size and Forecast, By End User
8.4.10. South Korea Cancer Ivd Market
8.4.10.1. Market Size and Forecast, By Product Type
8.4.10.2. Market Size and Forecast, By Technique
8.4.10.3. Market Size and Forecast, By Cancer Type
8.4.10.4. Market Size and Forecast, By End User
8.4.11. Australia Cancer Ivd Market
8.4.11.1. Market Size and Forecast, By Product Type
8.4.11.2. Market Size and Forecast, By Technique
8.4.11.3. Market Size and Forecast, By Cancer Type
8.4.11.4. Market Size and Forecast, By End User
8.4.12. Thailand Cancer Ivd Market
8.4.12.1. Market Size and Forecast, By Product Type
8.4.12.2. Market Size and Forecast, By Technique
8.4.12.3. Market Size and Forecast, By Cancer Type
8.4.12.4. Market Size and Forecast, By End User
8.4.13. Malaysia Cancer Ivd Market
8.4.13.1. Market Size and Forecast, By Product Type
8.4.13.2. Market Size and Forecast, By Technique
8.4.13.3. Market Size and Forecast, By Cancer Type
8.4.13.4. Market Size and Forecast, By End User
8.4.14. Indonesia Cancer Ivd Market
8.4.14.1. Market Size and Forecast, By Product Type
8.4.14.2. Market Size and Forecast, By Technique
8.4.14.3. Market Size and Forecast, By Cancer Type
8.4.14.4. Market Size and Forecast, By End User
8.4.15. Rest of Asia Pacific Cancer Ivd Market
8.4.15.1. Market Size and Forecast, By Product Type
8.4.15.2. Market Size and Forecast, By Technique
8.4.15.3. Market Size and Forecast, By Cancer Type
8.4.15.4. Market Size and Forecast, By End User
-
8.5. LAMEA
-
8.5.1. Key Market Trends and Opportunities
-
8.5.2. Market Size and Forecast, By Product Type
-
8.5.3. Market Size and Forecast, By Technique
-
8.5.4. Market Size and Forecast, By Cancer Type
-
8.5.5. Market Size and Forecast, By End User
-
8.5.6. Market Size and Forecast, By Country
8.5.7. Brazil Cancer Ivd Market
8.5.7.1. Market Size and Forecast, By Product Type
8.5.7.2. Market Size and Forecast, By Technique
8.5.7.3. Market Size and Forecast, By Cancer Type
8.5.7.4. Market Size and Forecast, By End User
8.5.8. South Africa Cancer Ivd Market
8.5.8.1. Market Size and Forecast, By Product Type
8.5.8.2. Market Size and Forecast, By Technique
8.5.8.3. Market Size and Forecast, By Cancer Type
8.5.8.4. Market Size and Forecast, By End User
8.5.9. Saudi Arabia Cancer Ivd Market
8.5.9.1. Market Size and Forecast, By Product Type
8.5.9.2. Market Size and Forecast, By Technique
8.5.9.3. Market Size and Forecast, By Cancer Type
8.5.9.4. Market Size and Forecast, By End User
8.5.10. UAE Cancer Ivd Market
8.5.10.1. Market Size and Forecast, By Product Type
8.5.10.2. Market Size and Forecast, By Technique
8.5.10.3. Market Size and Forecast, By Cancer Type
8.5.10.4. Market Size and Forecast, By End User
8.5.11. Argentina Cancer Ivd Market
8.5.11.1. Market Size and Forecast, By Product Type
8.5.11.2. Market Size and Forecast, By Technique
8.5.11.3. Market Size and Forecast, By Cancer Type
8.5.11.4. Market Size and Forecast, By End User
8.5.12. Rest of LAMEA Cancer Ivd Market
8.5.12.1. Market Size and Forecast, By Product Type
8.5.12.2. Market Size and Forecast, By Technique
8.5.12.3. Market Size and Forecast, By Cancer Type
8.5.12.4. Market Size and Forecast, By End User
-
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top Winning Strategies
9.3. Product Mapping Of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top Player Positioning, 2024
-
CHAPTER 10: COMPANY PROFILES
10.1. Roche Diagnostics
10.1.1. Company Overview
10.1.2. Key Executives
10.1.3. Company Snapshot
10.1.4. Operating Business Segments
10.1.5. Product Portfolio
10.1.6. Business Performance
10.1.7. Key Strategic Moves and Developments
10.2. Abbott Laboratories
10.2.1. Company Overview
10.2.2. Key Executives
10.2.3. Company Snapshot
10.2.4. Operating Business Segments
10.2.5. Product Portfolio
10.2.6. Business Performance
10.2.7. Key Strategic Moves and Developments
10.3. GlaxoSmithKline
10.3.1. Company Overview
10.3.2. Key Executives
10.3.3. Company Snapshot
10.3.4. Operating Business Segments
10.3.5. Product Portfolio
10.3.6. Business Performance
10.3.7. Key Strategic Moves and Developments
10.4. Qiagen NV
10.4.1. Company Overview
10.4.2. Key Executives
10.4.3. Company Snapshot
10.4.4. Operating Business Segments
10.4.5. Product Portfolio
10.4.6. Business Performance
10.4.7. Key Strategic Moves and Developments
10.5. Illumina, Inc.
10.5.1. Company Overview
10.5.2. Key Executives
10.5.3. Company Snapshot
10.5.4. Operating Business Segments
10.5.5. Product Portfolio
10.5.6. Business Performance
10.5.7. Key Strategic Moves and Developments
10.6. Siemens Healthineers
10.6.1. Company Overview
10.6.2. Key Executives
10.6.3. Company Snapshot
10.6.4. Operating Business Segments
10.6.5. Product Portfolio
10.6.6. Business Performance
10.6.7. Key Strategic Moves and Developments
10.7. Olympus Corporation
10.7.1. Company Overview
10.7.2. Key Executives
10.7.3. Company Snapshot
10.7.4. Operating Business Segments
10.7.5. Product Portfolio
10.7.6. Business Performance
10.7.7. Key Strategic Moves and Developments
10.8. Agilent Technologies
10.8.1. Company Overview
10.8.2. Key Executives
10.8.3. Company Snapshot
10.8.4. Operating Business Segments
10.8.5. Product Portfolio
10.8.6. Business Performance
10.8.7. Key Strategic Moves and Developments
10.9. Thermo Fisher Scientific Inc.
10.9.1. Company Overview
10.9.2. Key Executives
10.9.3. Company Snapshot
10.9.4. Operating Business Segments
10.9.5. Product Portfolio
10.9.6. Business Performance
10.9.7. Key Strategic Moves and Developments
10.10. Hologic, Inc.
10.10.1. Company Overview
10.10.2. Key Executives
10.10.3. Company Snapshot
10.10.4. Operating Business Segments
10.10.5. Product Portfolio
10.10.6. Business Performance
10.10.7. Key Strategic Moves and Developments
-
LIST OF TABLES
- TABLE 1. GLOBAL CANCER IVD MARKET, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 2. GLOBAL CANCER IVD MARKET FOR REAGENTS, BY REGION, 2025-2033 ($MILLION)
- TABLE 3. GLOBAL CANCER IVD MARKET FOR INSTRUMENTS, BY REGION, 2025-2033 ($MILLION)
- TABLE 4. GLOBAL CANCER IVD MARKET FOR SOFTWARE AND SERVICES, BY REGION, 2025-2033 ($MILLION)
- TABLE 5. GLOBAL CANCER IVD MARKET, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 6. GLOBAL CANCER IVD MARKET FOR BLOOD TESTING, BY REGION, 2025-2033 ($MILLION)
- TABLE 7. GLOBAL CANCER IVD MARKET FOR TISSUE DIAGNOSTICS, BY REGION, 2025-2033 ($MILLION)
- TABLE 8. GLOBAL CANCER IVD MARKET, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 9. GLOBAL CANCER IVD MARKET FOR BREAST CANCER, BY REGION, 2025-2033 ($MILLION)
- TABLE 10. GLOBAL CANCER IVD MARKET FOR COLORECTAL CANCER, BY REGION, 2025-2033 ($MILLION)
- TABLE 11. GLOBAL CANCER IVD MARKET FOR LUNG CANCER, BY REGION, 2025-2033 ($MILLION)
- TABLE 12. GLOBAL CANCER IVD MARKET FOR PROSTATE CANCER, BY REGION, 2025-2033 ($MILLION)
- TABLE 13. GLOBAL CANCER IVD MARKET FOR OTHER CANCER TYPES, BY REGION, 2025-2033 ($MILLION)
- TABLE 14. GLOBAL CANCER IVD MARKET, BY END USER, 2025-2033 ($MILLION)
- TABLE 15. GLOBAL CANCER IVD MARKET FOR STANDALONE LABORATORY, BY REGION, 2025-2033 ($MILLION)
- TABLE 16. GLOBAL CANCER IVD MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
- TABLE 17. GLOBAL CANCER IVD MARKET FOR ACADEMIC AND MEDICAL SCHOOLS, BY REGION, 2025-2033 ($MILLION)
- TABLE 18. GLOBAL CANCER IVD MARKET FOR OTHER END USER, BY REGION, 2025-2033 ($MILLION)
- TABLE 19. GLOBAL CANCER IVD MARKET, BY REGION, 2025-2033 ($MILLION)
- TABLE 20. NORTH AMERICA CANCER IVD, BY REGION, 2025-2033 ($MILLION)
- TABLE 21. NORTH AMERICA CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 22. NORTH AMERICA CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 23. NORTH AMERICA CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 24. NORTH AMERICA CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 25. U.S. CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 26. U.S. CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 27. U.S. CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 28. U.S. CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 29. CANADA CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 30. CANADA CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 31. CANADA CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 32. CANADA CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 33. MEXICO CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 34. MEXICO CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 35. MEXICO CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 36. MEXICO CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 37. EUROPE CANCER IVD, BY REGION, 2025-2033 ($MILLION)
- TABLE 38. EUROPE CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 39. EUROPE CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 40. EUROPE CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 41. EUROPE CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 42. FRANCE CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 43. FRANCE CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 44. FRANCE CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 45. FRANCE CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 46. GERMANY CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 47. GERMANY CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 48. GERMANY CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 49. GERMANY CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 50. ITALY CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 51. ITALY CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 52. ITALY CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 53. ITALY CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 54. SPAIN CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 55. SPAIN CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 56. SPAIN CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 57. SPAIN CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 58. UK CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 59. UK CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 60. UK CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 61. UK CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 62. RUSSIA CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 63. RUSSIA CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 64. RUSSIA CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 65. RUSSIA CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 66. REST OF EUROPE CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 67. REST OF EUROPE CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 68. REST OF EUROPE CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 69. REST OF EUROPE CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 70. ASIA-PACIFIC CANCER IVD, BY REGION, 2025-2033 ($MILLION)
- TABLE 71. ASIA-PACIFIC CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 72. ASIA-PACIFIC CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 73. ASIA-PACIFIC CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 74. ASIA-PACIFIC CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 75. CHINA CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 76. CHINA CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 77. CHINA CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 78. CHINA CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 79. JAPAN CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 80. JAPAN CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 81. JAPAN CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 82. JAPAN CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 83. INDIA CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 84. INDIA CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 85. INDIA CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 86. INDIA CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 87. SOUTH KOREA CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 88. SOUTH KOREA CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 89. SOUTH KOREA CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 90. SOUTH KOREA CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 91. AUSTRALIA CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 92. AUSTRALIA CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 93. AUSTRALIA CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 94. AUSTRALIA CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 95. THAILAND CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 96. THAILAND CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 97. THAILAND CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 98. THAILAND CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 99. MALAYSIA CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 100. MALAYSIA CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 101. MALAYSIA CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 102. MALAYSIA CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 103. INDONESIA CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 104. INDONESIA CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 105. INDONESIA CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 106. INDONESIA CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 107. REST OF ASIA PACIFIC CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 108. REST OF ASIA PACIFIC CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 109. REST OF ASIA PACIFIC CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 110. REST OF ASIA PACIFIC CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 111. LAMEA CANCER IVD, BY REGION, 2025-2033 ($MILLION)
- TABLE 112. LAMEA CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 113. LAMEA CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 114. LAMEA CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 115. LAMEA CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 116. BRAZIL CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 117. BRAZIL CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 118. BRAZIL CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 119. BRAZIL CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 120. SOUTH AFRICA CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 121. SOUTH AFRICA CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 122. SOUTH AFRICA CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 123. SOUTH AFRICA CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 124. SAUDI ARABIA CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 125. SAUDI ARABIA CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 126. SAUDI ARABIA CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 127. SAUDI ARABIA CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 128. UAE CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 129. UAE CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 130. UAE CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 131. UAE CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 132. ARGENTINA CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 133. ARGENTINA CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 134. ARGENTINA CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 135. ARGENTINA CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 136. REST OF LAMEA CANCER IVD, BY PRODUCT TYPE, 2025-2033 ($MILLION)
- TABLE 137. REST OF LAMEA CANCER IVD, BY TECHNIQUE, 2025-2033 ($MILLION)
- TABLE 138. REST OF LAMEA CANCER IVD, BY CANCER TYPE, 2025-2033 ($MILLION)
- TABLE 139. REST OF LAMEA CANCER IVD, BY END USER, 2025-2033 ($MILLION)
- TABLE 140. ROCHE DIAGNOSTICS: KEY EXECUTIVES
- TABLE 141. ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
- TABLE 142. ROCHE DIAGNOSTICS: OPERATING SEGMENTS
- TABLE 143. ROCHE DIAGNOSTICS: PRODUCT PORTFOLIO
- TABLE 144. ROCHE DIAGNOSTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 145. ABBOTT LABORATORIES: KEY EXECUTIVES
- TABLE 146. ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 147. ABBOTT LABORATORIES: OPERATING SEGMENTS
- TABLE 148. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 149. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 150. GLAXOSMITHKLINE: KEY EXECUTIVES
- TABLE 151. GLAXOSMITHKLINE: COMPANY SNAPSHOT
- TABLE 152. GLAXOSMITHKLINE: OPERATING SEGMENTS
- TABLE 153. GLAXOSMITHKLINE: PRODUCT PORTFOLIO
- TABLE 154. GLAXOSMITHKLINE: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 155. QIAGEN NV: KEY EXECUTIVES
- TABLE 156. QIAGEN NV: COMPANY SNAPSHOT
- TABLE 157. QIAGEN NV: OPERATING SEGMENTS
- TABLE 158. QIAGEN NV: PRODUCT PORTFOLIO
- TABLE 159. QIAGEN NV: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 160. ILLUMINA, INC.: KEY EXECUTIVES
- TABLE 161. ILLUMINA, INC.: COMPANY SNAPSHOT
- TABLE 162. ILLUMINA, INC.: OPERATING SEGMENTS
- TABLE 163. ILLUMINA, INC.: PRODUCT PORTFOLIO
- TABLE 164. ILLUMINA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 165. SIEMENS HEALTHINEERS: KEY EXECUTIVES
- TABLE 166. SIEMENS HEALTHINEERS: COMPANY SNAPSHOT
- TABLE 167. SIEMENS HEALTHINEERS: OPERATING SEGMENTS
- TABLE 168. SIEMENS HEALTHINEERS: PRODUCT PORTFOLIO
- TABLE 169. SIEMENS HEALTHINEERS: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 170. OLYMPUS CORPORATION: KEY EXECUTIVES
- TABLE 171. OLYMPUS CORPORATION: COMPANY SNAPSHOT
- TABLE 172. OLYMPUS CORPORATION: OPERATING SEGMENTS
- TABLE 173. OLYMPUS CORPORATION: PRODUCT PORTFOLIO
- TABLE 174. OLYMPUS CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 175. AGILENT TECHNOLOGIES: KEY EXECUTIVES
- TABLE 176. AGILENT TECHNOLOGIES: COMPANY SNAPSHOT
- TABLE 177. AGILENT TECHNOLOGIES: OPERATING SEGMENTS
- TABLE 178. AGILENT TECHNOLOGIES: PRODUCT PORTFOLIO
- TABLE 179. AGILENT TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 180. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
- TABLE 181. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
- TABLE 182. THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
- TABLE 183. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
- TABLE 184. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 185. HOLOGIC, INC.: KEY EXECUTIVES
- TABLE 186. HOLOGIC, INC.: COMPANY SNAPSHOT
- TABLE 187. HOLOGIC, INC.: OPERATING SEGMENTS
- TABLE 188. HOLOGIC, INC.: PRODUCT PORTFOLIO
- TABLE 189. HOLOGIC, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
-
LIST OF FIGURES
- FIGURE 1. GLOBAL CANCER IVD MARKET SEGMENTATION
- FIGURE 2. GLOBAL CANCER IVD MARKET
- FIGURE 3. SEGMENTATION CANCER IVD MARKET
- FIGURE 4. TOP INVESTMENT POCKET IN CANCER IVD MARKET
- FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 8. LOW THREAT OF SUBSTITUTION
- FIGURE 9. HIGH COMPETITIVE RIVALRY
- FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCANCER IVD MARKET
- FIGURE 11. CANCER IVD MARKET SEGMENTATION, BY BY PRODUCT TYPE
- FIGURE 12. CANCER IVD MARKET FOR REAGENTS, BY COUNTRY, 2025-2033 ($MILLION)
- FIGURE 13. CANCER IVD MARKET FOR INSTRUMENTS, BY COUNTRY, 2025-2033 ($MILLION)
- FIGURE 14. CANCER IVD MARKET FOR SOFTWARE AND SERVICES, BY COUNTRY, 2025-2033 ($MILLION)
- FIGURE 15. CANCER IVD MARKET SEGMENTATION, BY BY TECHNIQUE
- FIGURE 16. CANCER IVD MARKET FOR BLOOD TESTING, BY COUNTRY, 2025-2033 ($MILLION)
- FIGURE 17. CANCER IVD MARKET FOR TISSUE DIAGNOSTICS, BY COUNTRY, 2025-2033 ($MILLION)
- FIGURE 18. CANCER IVD MARKET SEGMENTATION, BY BY CANCER TYPE
- FIGURE 19. CANCER IVD MARKET FOR BREAST CANCER, BY COUNTRY, 2025-2033 ($MILLION)
- FIGURE 20. CANCER IVD MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2025-2033 ($MILLION)
- FIGURE 21. CANCER IVD MARKET FOR LUNG CANCER, BY COUNTRY, 2025-2033 ($MILLION)
- FIGURE 22. CANCER IVD MARKET FOR PROSTATE CANCER, BY COUNTRY, 2025-2033 ($MILLION)
- FIGURE 23. CANCER IVD MARKET FOR OTHER CANCER TYPES, BY COUNTRY, 2025-2033 ($MILLION)
- FIGURE 24. CANCER IVD MARKET SEGMENTATION, BY BY END USER
- FIGURE 25. CANCER IVD MARKET FOR STANDALONE LABORATORY, BY COUNTRY, 2025-2033 ($MILLION)
- FIGURE 26. CANCER IVD MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
- FIGURE 27. CANCER IVD MARKET FOR ACADEMIC AND MEDICAL SCHOOLS, BY COUNTRY, 2025-2033 ($MILLION)
- FIGURE 28. CANCER IVD MARKET FOR OTHER END USER, BY COUNTRY, 2025-2033 ($MILLION)
- FIGURE 29. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
- FIGURE 30. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
- FIGURE 31. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
- FIGURE 32. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 33. COMPETITIVE DASHBOARD
- FIGURE 34. COMPETITIVE HEATMAP: CANCER IVD MARKET
- FIGURE 35. TOP PLAYER POSITIONING, 2024
- FIGURE 36. ROCHE DIAGNOSTICS: NET SALES, 2022-2024 ($MILLION)
- FIGURE 37. ROCHE DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2024 (%)
- FIGURE 38. ROCHE DIAGNOSTICS: REVENUE SHARE, BY REGION, 2024 (%)
- FIGURE 39. ABBOTT LABORATORIES: NET SALES, 2022-2024 ($MILLION)
- FIGURE 40. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
- FIGURE 41. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
- FIGURE 42. GLAXOSMITHKLINE: NET SALES, 2022-2024 ($MILLION)
- FIGURE 43. GLAXOSMITHKLINE: REVENUE SHARE, BY SEGMENT, 2024 (%)
- FIGURE 44. GLAXOSMITHKLINE: REVENUE SHARE, BY REGION, 2024 (%)
- FIGURE 45. QIAGEN NV: NET SALES, 2022-2024 ($MILLION)
- FIGURE 46. QIAGEN NV: REVENUE SHARE, BY SEGMENT, 2024 (%)
- FIGURE 47. QIAGEN NV: REVENUE SHARE, BY REGION, 2024 (%)
- FIGURE 48. ILLUMINA, INC.: NET SALES, 2022-2024 ($MILLION)
- FIGURE 49. ILLUMINA, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
- FIGURE 50. ILLUMINA, INC.: REVENUE SHARE, BY REGION, 2024 (%)
- FIGURE 51. SIEMENS HEALTHINEERS: NET SALES, 2022-2024 ($MILLION)
- FIGURE 52. SIEMENS HEALTHINEERS: REVENUE SHARE, BY SEGMENT, 2024 (%)
- FIGURE 53. SIEMENS HEALTHINEERS: REVENUE SHARE, BY REGION, 2024 (%)
- FIGURE 54. OLYMPUS CORPORATION: NET SALES, 2022-2024 ($MILLION)
- FIGURE 55. OLYMPUS CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
- FIGURE 56. OLYMPUS CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
- FIGURE 57. AGILENT TECHNOLOGIES: NET SALES, 2022-2024 ($MILLION)
- FIGURE 58. AGILENT TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
- FIGURE 59. AGILENT TECHNOLOGIES: REVENUE SHARE, BY REGION, 2024 (%)
- FIGURE 60. THERMO FISHER SCIENTIFIC INC.: NET SALES, 2022-2024 ($MILLION)
- FIGURE 61. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
- FIGURE 62. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE, BY REGION, 2024 (%)
- FIGURE 63. HOLOGIC, INC.: NET SALES, 2022-2024 ($MILLION)
- FIGURE 64. HOLOGIC, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
- FIGURE 65. HOLOGIC, INC.: REVENUE SHARE, BY REGION, 2024 (%)
Purchase Full Report of
Cancer IVD Market